Program
MER511
A development code. Also written as “MER511 (IV)”, “MER511 (SC)” and “MER511 (SC) for MAD”.
Its studies are mostly in Graves Disease, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 11 open or running | phase 1since Dec 12, 2025 | Dec 12, 2025 | Jul 24, 2028phase 1 · NCT07305818 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2025First study: phase 1 study in Graves DiseaseFirst studyNCT07305818 · 100 planned · United States, Spain
Ahead
- Jul 24, 2028Primary completion: phase 1 study in Graves DiseaseNCT07305818
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07305818Graves Disease · United States, Spain | 1 | Recruiting | Jul 24, 2028 | 100 |
How it is read
Names in the registry
- “MER511 (IV)”, 1 entry
- “MER511 (SC)”, 1 entry
- “MER511 (SC) for MAD”, 1 entry
Codes read as this program: MER511.
Conditions, from the studies’ own filings
- Graves Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.